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LOCALIZING GLUCOSE TRANSPORT PROTEINS: 
ACTIVE INVESTIGATION OF PASSIVE CARRIERS 
Thorens B, Cheng 2-Q, Brown D, Lodish HF. Liver 
glucose transporter: a basolateral protein in hepatocytes 
and intestine and kidney cells. Am J Physiol 1990;259: 
C279-C285. 
ABSTRACT 
The “liver” isoform of the facilitated diffusion 
glucose transporter is expressed predominantly in 
liver, intestine, kidney, and pancreatic islet p-cells. The 
apparent molecular mass of the transporter in liver, 
kidney, and intestine is different, as detected by 
Western blot analysis of membrane proteins using 
antipeptide antibodies. However, as assessed by 
Northern blot analysis and molecular cloning, the same 
mRNA is expressed in these tissues, indicating that 
there are tissue-specific posttranslational modifica- 
tions of the same transporter polypeptide. As deter- 
mined by immunofluorescence analysis on frozen 
tissue sections, the liver glucose transporter is present 
on the sinusoidal membrane of hepatocytes, on the 
basolateral membrane of fully differentiated ab- 
sorptive intestine epithelial cells, and on the baso- 
lateral membrane of proximal tubule cells of the 
kidney nephron. This localization is consistent with 
the involvement of the liver glucose transporter in 
several key steps of glucose metabolism: glucose 
uptake and release by the liver and absorption or 
reabsorption by epithelial cells of the intestine and 
kidney, respectively. 
Thorens B, Lodish HF, Brown D. Differential local- 
ization of two glucose transporter iso-forms in rat 
kidney. Am J Physiol 1990;259:C268-C294. 
ABSTRACT 
The localization of two glucose transporter isoforms 
was mapped in the rat kidney: the high-Michaelis 
constant (k; 15-20mM) low-affinity “liver” trans- 
porter and the low-Y, (1-2mM) high-affinity ery- 
throimrain transporter. Both are basolateral mem- 
brane proteins, but the liver transporter was present 
exclusively in the S, part of the proximal tubule, 
whereas the erythroidmrain transporter was ex- 
pressed at variable levels in different nephron seg- 
ments. Staining intensity was low in the straight 
proximal tubule (S3), intermediate in the medullary 
thin and thick ascending limbs, and highest in con- 
necting segments and collecting ducts. In the col- 
lecting duct, the erythroidmrain glucose transporter 
was expressed at the highest level in intercalated cells; 
less was present in principal cells. In the papilla, only 
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intercalated cells expressed this transporter isoform. 
These results suggest specific involvement of each 
transporter isoform in transepithelial glucose reab- 
sorption by different segments of the proximal tubule. 
They also indicate that while the liver glucose trans- 
porter is present in gluconeogenic cells, there is a good 
correlation between the level of expression of the 
erythroimrain glucose transporter and the glycolytic 
activity of the different nephron segments. 
COMMENTS 
Glucose, an essential, water-soluble nutrient, requires 
specific transport proteins to traverse the plasma mem- 
brane’s hydrophobic core. Thus far, two distinct classes 
of membrane-embedded glucose transport proteins have 
been identified. One type actively transports glucose 
against its concentration gradient, energized by the 
simultaneous downhill transport of sodium. The more 
frequently encountered form of glucose-carrier protein 
passively catalyzes glucose transport down its concen- 
tration gradient, a process termed facilitated diffusion. 
These passive glucose transporters or carriers are found 
in a variety of cells and are involved with import or 
export of glucose across the plasma membrane. In 
glucose-transporting epithelia such as intestine and 
kidney, the passive glucose transport proteins have been 
thought to be present in the basolateral membrane, 
facilitating exit of glucose pumped into the cell by 
brush-border membran+active glucose transporters. 
Passive glucose carriers also enable glucose entry into 
cells for glycolysis or permit exit of glycogenolytic or 
gluconeogenic products. Interestingly, the active and 
passive glucose transport proteins, with the exception of 
sharing primary substrate and being located in the 
plasma membrane, are distinct in terms of inhibitors, 
structural specificity of substrates and primary 
structure (1 -3). 
Cells whose main function is to metabolize glucose 
taken up from extracellular fluid such as erythrocytes 
and brain have a high-dfinity (uptake K, = 1 to 
2 mmoliL) transporter that would be nearly saturated at 
a typical plasma glucose concentration of 5 mmol/L. 
Adipocyte glucose uptake also occurs by way of a related 
system, which differs from the erythrocyte system in 
that V,, is regulated by insulin (4). In contrast, liver 
sinusoidal membranes contain a low-affinity (uptake 
Km > 20 mmol/L) glucose transporter (5). Glucose can 
move in either direction across the hepatocyte sinusoidal 
membrane, with efflux occurring in the fed state, when 
intracellular concentrations can exceed those in plasma 
(6). Intestinal basolateral membranes and a few other 
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tissues share a similar low-affinity glucose carrier. In 
cells with low-affinity glucose transport, glucose 
movement is primarily efflux because the glucose con- 
centration in these cells surpasses that in plasma. 
Corresponding to the three physiological types of 
glucose transport just described, three major isoforms of 
the glucose transporter have been cloned. One type is the 
“erythroidbrain,” also termed “brain/HepG2” because 
clones sequenced from the human HCC cell line HepG2, 
red cells and brain are nearly homologous (7). The 
second isoform is the “liver” transporter, obtained from 
hepatic complementary DNA (cDNA) libraries. It has 
also been found in pancreatic islet p cells, intestine and 
kidney (8). The third isoform is the “muscle/adipocyte” 
isoform found in heart, skeletal muscle and fat cells (4). 
The three isoforms share considerable homology in the 
putative membrane spanning segments but less so in 
other regions, resulting in roughly 60% overall ho- 
mology between isoforms. 
In the articles under consideration, passive glucose 
transport proteins were immunolocalized in liver, 
small intestine and kidney with antibodies prepared 
against synthetic peptides unique to the liver and 
erythroidbrain isoforms. They confirm the physio- 
logical prediction that passive glucose carriers should 
only exist in blood-facing or basolateral surfaces of 
epithelia. 
In the paper addressing the glucose carrier of liver, 
intestine and kidney, immunoblots of hepatic, renal and 
intestinal membranes revealed that protein recognized 
by glucose antibody differed in molecular mass ac- 
cording to the source tissue. Restriction maps demon- 
strated that the passive glucose carrier in liver, kidney 
and intestine, despite differences in protein size, had 
nearly identical nucleotide sequences and thus belonged 
to the same “liver” isoform. Immunostaining with 
“liver” glucose carrier antibodies revealed staining of 
the sinusoidal membranes, with absence of staining of 
the canalicuIar-associated membranes (identified with a 
second antibody). In the small intestine, glucose carriers 
were immunolocalized to the basolateral membrane of 
differentiated surface cells. This finding confirms the 
notion, inferred from whole-tissue data, that the surface 
cells, and not the crypt cells, mediate intestinal glucose 
transport and that passive glucose carriers convey 
intracellular glucose into the blood. In the kidney, the 
liver isoform was localized to the basolateral membrane 
of the proximal convoluted tubule, again, as would be 
predicted for a protein involved with transepithelial 
glucose movement. 
The second paper examines the distribution of the 
erythroidhrain glucose transporter isoform in kidney. 
This isoform was located in the basolateral membranes 
of cells in a variety of segments of nephron. In the 
intercalated and principal cells, differentiated by immu- 
nostaining with H + -ATPase antibody, staining was most 
intense in the intercalated cells of the collecting duct. 
In discussing their findings, the authors conclude that 
the liver-type transporter is found in cells that export 
glucose into blood, whereas the erythroidhrain isoform 
is found in cells taking up glucose from plasma. 
Collecting duct intercalated cells, which have high 
energy requirements because of the presence of plasma 
membrane proton pumps, thus have the highest density 
of glucose transporters. 
Taken together, the papers represent an important 
contribution to the understanding of glucose transport 
across epithelial basolateral membranes. With tech- 
nology able to  unequivocally localize glucose transporter 
isoforms in tissue, it was possible to discriminate 
between transporter subtypes in tissues such as kidney, 
where more than one form exists. Immunolocalization 
thus has clear advantages in this regard over alterna- 
tive technologies such as whole tissue perfusions or 
transport measurements with membrane vesicles, 
which are generally confounded by the presence of more 
than one type of carrier. The methodology can also be 
used to study regulation, such as in recent publications 
in which cDNA probes and specific antibodies were used 
to examine glucose carrier regulation in response to 
regeneration and diabetes (9, 10). 
A few comments might also be added that in no way 
diminish the superb contributions these papers rep- 
resent. The authors propose in the second paper that the 
presence of the high-affinity liver-type transporter in the 
S, segment of proximal tubule implied that these cells 
might have high-affinity active glucose transporters in 
the brush border. Because the affinity of the basolateral 
carrier is dependent on intracellular concentrations, 
carrier affinity does not necessarily have to increase in 
concert with the brush-border carrier. Also, it would be 
interesting to follow up on an earlier observation that 
the muscle/adipocyte isoform is present in the kidney 
(4). Because the liver is one of the few organs in which 
bidirectional glucose transport occurs across the same 
membrane, it would also be intriguing to see whether the 
sinusoidal membrane has more than one glucose 
transport protein. 
A striking clinical correlate to the tissue distribution 
of glucose transport proteins is the distribution of the 
antineoplastic drug streptozotocin (STZ). STZ is a 
glucopyranoside that is taken up by liver, kidney, 
intestine and pancreatic p cells, exactly corresponding to 
the distribution of liver-type glucose transporters. That 
the glucose moiety is important for the drug’s activity is 
suggested by studies by Kawada et al. (11) who demon- 
strated that STZ analogs with altered sugar moieties 
were not taken up by tissues and were not cytotoxic. It 
is also known that the bactericidal effect of STZ is 
dependent on the presence of specific bacterial transport 
proteins, which take up the drug from the surrounding 
medium. STZ is cytotoxic for pancreatic p cells in rats 
and proximal nephron in humans, both sites of the liver 
glucose transporter. The finding of liver-type glucose 
transport protein RNA in insulinoma cells is consistent 
with the therapeutic use of STZ in pancreatic islet-cell 
tumor. With antibodies and cDNA probes, it should be 
possible to confirm the hypothesis that STZ cytotoxicity 
is caused by the presence of a liver-type glucose 
transporter that facilitates entry of STZ into cells. 
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In summary, the two papers show that the low-affinity 
liver isoform of glucose transporter is found in cells that 
primarily export glucose, such as those cells involved 
with transepithelial glucose transport or gluconeo- 
genesis, whereas the high-affinity erythrocytelbrain 
transporter is found in cells that primarily take up 
glucose from plasma. Important and novel aspects of 
these studies include the demonstration of two types of 
transporters coexisting in the kidney, the type and 
density correlating with direction of transport (influx or 
efflux) and energy requirements, and the localization of 
a liver-type glucose carrier to  the basolateral membrane 
of differentiated small intestinal surface cells, con- 
firming their role in nutrient absorption. Unques- 
tionably, a new and useful research tool for studying 
transmembrane glucose transport has been added to the 
investigator’s armamentarium. 
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TREATMENT OF HEPATOCELLULAR CARCINOMA 
Venook AP, Stagg RJ, Lewis BJ, Chase JL ,  Ring EJ, 
Maroney TP, Hohn DC. Chemoembolization for hepa- 
tocellular carcinoma. J Clin Oncol 1990;8:1108-1114. 
ABSTRACT 
Fifty-one patients with unresectable hepatocellular 
carcinoma were treated by embolization of the hepatic 
artery with Gelfoam powder, contrast material and 
three chemotherapeutic agents (doxorubicin, mito- 
mycin, cisplatin). Twelve patients (24%) had a partial 
response with a decrease in the tumor diameter by at 
least 50%, 13 patients (26%) had only minor responses, 
12 (24%) had stabilization of disease and the remainder 
had progressive disease. Tumor liquefaction was noted 
on computed tomographic scanning in 70% of patients, 
and 23 of 34 patients with elevations in serum alpha- 
fetoprotein values had a greater than 50% reduction 
following treatment. The median patient survival time 
from treatment was 207 days. Most patients experi- 
enced transient pain, fever, nausea and elevations in 
serum aminotransferase activities as a result of 
therapy. Ascites developed in 14 patients. There were 
two treatment-related deaths: one from tumor hemor- 
rhage and one from liver failure. Chemoembolization 
therefore appears to have significant activity in pa- 
tients with hepatocellular carcinoma and is relatively 
well tolerated. 
Franco D, Capussotti L, Smadja C, Bouzari H, Meakins 
J ,  Kemeny F, Grange D, et al. Resection of hepatocellular 
carcinoma: results in 72 European patients with cir- 
rhosis. Gastroenterology 1990;98:733-738. 
ABSTRACT 
This study reports the results of resection in 72 
cirrhotic patients with hepatocellular carcinoma from 
Europe. One and 3 year survival rates were 68% and 
51% respectively. Survival was significantly higher in 
Child’s class A than in class B or C patients. Patients 
with a thickly encapsulated tumor lived longer than 
those with an infiltrating tumor and also had a signif- 
icantly lower recurrence rate. There was no rela- 
tionship between the size of the tumor or the presence 
of symptoms and survival. These data suggest that good 
results can be achieved by resection of hepatocellular 
carcinoma in European cirrhotic patients. A thickly 
encapsulated tumor and good liver function are the 
main determinants of low cancer recurrence and high 
survival. 
COMMENTS 
HCC is one of the most common cancers worldwide, 
although it occurs relatively infrequently in the de- 
veloped Western world (1). Typically HCC is seen at an 
advanced stage with extensive intrahepatic disease and 
metastases to lung, bone, adrenal gland or regional 
lymph nodes. It is also usually associated with sig- 
nificant liver disease, particularly cirrhosis (2). Because 
of this late presentation and association with cirrhosis, 
HCC has a grave prognosis, with survival times being 
measured in weeks to months. No effective therapy has 
been available for advanced HCC, although surgical 
resection has been considered potentially curative if 
carried out at an early stage. Within the past few years, 
a significant shift in emphasis has occurred with the 
attempt to diagnose HCC at an early, asymptomatic 
